Form 4: Nektar Therapeutics Chief R&D Officer Sells Shares to Cover Tax Obligations

Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, sold 7,785 shares of common stock to cover tax obligations related to vesting RSUs.

Summary

• Jonathan Zalevsky, Chief R&D Officer at Nektar Therapeutics, sold 7,785 shares of common stock on November 19, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.01, with individual trades ranging from $1.00 to $1.04.
• Following the transaction, Zalevsky directly owns 243,019 shares of Nektar Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when RSUs vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the biotechnology and pharmaceutical industries.
• Many companies use RSUs as part of their compensation packages, leading to similar transactions by executives at other firms.
• The sale of 7,785 shares is not unusual for an executive at a company of Nektar's size.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.

Key Dates

Keywords

Nektar Therapeutics, Jonathan Zalevsky, stock sale, Form 4, insider trading, RSU, tax obligations, executive compensation